Organovo Inc. (ONVO)
0.34
-0.01 (-3.95%)
At close: Jan 15, 2025, 3:59 PM
0.35
1.45%
After-hours Jan 15, 2025, 04:11 PM EST
Company Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Organovo Inc.
| Country | United States |
| IPO Date | Feb 14, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Keith E. Murphy |
Contact Details
Address: 11555 Sorrento Valley Road Solana Beach, California United States | |
| Website | https://www.organovo.com |
Stock Details
| Ticker Symbol | ONVO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001497253 |
| CUSIP Number | 68620A203 |
| ISIN Number | US68620A2033 |
| Employer ID | 27-1488943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Norman Staskey | President, Chief Financial Officer & Principal Financial Officer |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy & Business Development |
| Keith E. Murphy | Executive Chairman & Corporate Secretary |
| Vaidehi Joshi | Director of Discovery Biology & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | 3 | Filing |
| Dec 31, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Oct 25, 2024 | S-1 | Filing |
| Oct 07, 2024 | DEFA14A | Filing |
| Oct 07, 2024 | DEF 14A | Filing |
| Sep 18, 2024 | PRE 14A | Filing |
| Aug 09, 2024 | 8-K | Current Report |